ReproCell Stock

ReproCell Debt Growth

The Year-over-Year Debt Growth of ReproCell (4978.T) as of Sep 4, 2026 is 39.98 %. In the previous year, Year-over-Year Debt Growth was -2.94 % — a change of -1,460.58% (higher).

Debt Growth

39.98 %

YoY

-1,460.58%

Last updated:

Year-over-Year Debt Growth of ReproCell is 2026 39.98 % . Year-over-Year Debt Growth of ReproCell was 2025 -2.94 % . It decreases by -1,460.58% higher compared to the previous year.

The ReproCell Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2016
14.28 JPY
Jan 1, 2017
-6.31 JPY
Jan 1, 2018
-3.71 JPY
Jan 1, 2019
-3.01 JPY
Jan 1, 2020
0.00 JPY
Jan 1, 2021
0.00 JPY
Jan 1, 2022
0.00 JPY
Jan 1, 2023
-100.00 JPY
The ReproCell Debt Growth history
YEARDebt GrowthYoY
-100.00 %
0.00
0.00
0.00-100.00%
-3.01 %-18.88%
-3.71 %-41.26%
-6.31 %-144.19%
14.28 %
0.00
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Year-over-Year Debt Growth of ReproCell is 39.98 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth ReproCell since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's ReproCell historically and in real time.

Access this data via the Eulerpool API

Growth — ReproCell

All Key Metrics — ReproCell